bio-rad laboratories

Jefferies, which raised its PT on shares of Bio-Rad Laboratories, Inc. (NYSE: BIO), is providing some color on the stock. “BIO's adjusted 1Q11 EPS of $1.26 was $0.06 below consensus as a higher tax rate and below the line items offset a better than expected revenue growth experience,” Jefferies...

Jefferies & Company has raised the price target on Bio-Rad Laboratories (NYSE: BIO) from $127 to $145 and maintains its Buy rating.

Jefferies & Co has published a research report on Bio-Rad Laboratories (NYSE: BIO) after the company shows its signs of refinancing debt and raising forecasts. In the report, Jefferies writes "BIO will redeem all of its 7.5% ($225M) and 6.125% senior subordinate notes ($200M) through the...